BBB Delivery The company specializes in delivering biologics across the blood-brain barrier using a shark-derived VNAR platform, indicating strong potential for collaborations with pharma seeking CNS-targeted therapies and brain-penetrant biologics.

Strategic Partnerships Past and ongoing collaborations with Lundbeck, Novo Nordisk, and UK science parks suggest a readiness to partner on neurodegeneration, ALS, pain, and metabolic disease programs, presenting outbound opportunities for co-development or licensing deals.

Clinical Readiness As a privately held preclinical company with revenue in the low-to-mid single digits, Ossianix appears positioned to monetize its BBB shuttle technology through partnerships or out-licensing of higher-value CNS programs rather than standalone products.

Global Footprint Operations and labs in both the United States and United Kingdom imply capacity to engage international partners, prospective grant funding, and cross-border collaborations to accelerate CNS-targeted candidate programs.

Targeted Markets Current focus areas include neurodegeneration, neuro-oncology, ALS, pain, and botulism, aligning with high-need therapeutic areas where brain delivery is a bottleneck and where strategic alliances can unlock access to novel CNS modalities.